Oritavancin

Background: Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.

On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.

Indication: 用于治疗由下列易感分离株革兰氏阳性微生物所致急性细菌皮肤和皮肤结构感染(ABSSSI)成年患者的治疗。如金黄色葡萄球菌(包括甲氧西林-易感和甲氧西林–耐药分离株)，化脓性链球菌，无乳链球菌，停乳链球菌，咽峡炎链球菌群(包括咽颊炎链球菌，中间型链球菌,和星座链球菌)，和粪肠球菌(万古霉素-仅易感分离株)。